The regulatory sciences for stem cell-based medicinal products

ISSCR Guidelines for Clinical Translation of Stem Cells. 2008 De Miguel MP, Fuentes-Julián S, Blázquez-Martínez A, Pascual CY, Aller MA, Arias J, Arnalich-Montiel F. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med 2012; 12(5): 574–591 FDA. Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs). 2008 Chinese Ministry of Health and Family Planning & China Food and Drug Control Document. Interim Regulatory Guidance: guidelines for quality control and preclinical studies of the stem cell medicinal products. 2013 Elmgren L, Li X, Wilson C, Ball R, Wang J, Cichutek K, Pfleiderer M, Kato A, Cavaleri M, Southern J, Jivapaisarnpong T, Minor P, Griffiths E, Sohn Y, Wood D. A global regulatory science agenda for vaccines. Vaccine 2013; 31(Suppl 2): B163–B175 NIH. Stem Cell Therapy (keywords) in http://www.clinicaltrials.gov. 2014 Olausson M. Bioengineered vascular graft with autologous stem cells: first use in the clinic. Regen Med 2012; 7(6 Suppl): 12–15 Schulman IH, Hare JM. Key developments in stem cell therapy in cardiology. Regen Med 2012; 7(6 Suppl): 17–24 Blenkinsop TA, Corneo B, Temple S, Stern JH. Ophthalmologic stem cell transplantation therapies. Regen Med 2012; 7(6 Suppl): 32–39 Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G, Monroy R, Kurtzberg J. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011; 17(4): 534–541 Bersenev A. Regenerative Medicine and Cell Therapy Industry in 2012. RegenMed Digest. 2012. http://stemcellassays.com/2012/12/industry-2012/ Barker RA. Stem cells and neurodegenerative diseases: where is it all going? Regen Med 2012; 7(6 Suppl): 26–31 Grant B. First Ever iPS-Cell Trial a Go. The Scientist. July 22, 2013; http://www.the-scientist.com/?articles.view/articleNo/36623/title/First-Ever-iPS-Cell-Trial-a-Go/ Annual Report ARM. Cellular Reprogramming and Disease Modeling. 2013. 24–26 Bersenev A. Regenerative Medicine and Cell Therapy Industry in 2011. RegenMed Digest. 2011. http://stemcellassays.com/2011/12/industry-2011/ Bersenev A. Alliance for Regenerative Medicine’s 2012 Report. RegenMed Digest. 2012. http://stemcellassays.com/2012/05/alliance-regenerative-medicines-2012-report/ McMahon DS, Thorsteinsdóttir H, Singer PA, Daar AS. Cultivating regenerative medicine innovation in China. Regen Med 2010; 5(1): 35–44 Ministry of Heath Reports. Surveys of Stem Cell Clinical Studies and Uses in China. 2012 Chinese Ministry of Health and Family Planning & China Food and Drug Control Document. Interim Regulatory Guidance: general requirements for conducting clinical studies of the stem cell-based medicinal products. 2013 Chinese Ministry of Health and Family Planning & China Food and Drug Control Document. Interim Regulatory Guidance: qualification for institutions conducting studies of the stem cell-based medicinal products. 2013 Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8(4): 315–317 Herberts CA, Kwa MS, Hermsen HP. Risk factors in the development of stem cell therapy. J Transl Med 2011; 9(1): 29 EMA. Guideline on Human Cell-Based Medicinal Products. 2007 EMA. Reflection Paper on Stem Cell-Based Medicinal Pproducts. 2011 FDA. Guidance for Human Somatic Cell Therapy and Gene Therapy. 1998 Chinese Pharmacopoeia Commission. Chinese Pharmacopoeia. 2010 Version. Part III. Beijing: China Medical Science Press. 2010 SFDA. Guidelines for Clinical Studies and Quality Control of Human Somatic Cells 2003. (in Chinese) WHO. Recommendations for the Evaluation of Animal Cell Cultures as Substrates for the Manufacture of Biological Medicinal Products and for the Characterization of Cell Banks. 2010 FDA. Guidance for Industry—Current Good Tissue Practice (CGTP) and Additional Requirements for Manufactures of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). 2009 Tarte K, Gaillard J, Lataillade JJ, Fouillard L, Becker M, Mossafa H, Tchirkov A, Rouard H, Henry C, Splingard M, Dulong J, Monnier D, Gourmelon P, Gorin NC, Sensebé L; Société Française de Greffe de Moelle et Thérapie Cellulaire. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 2010; 115(8): 1549–1553 Lepperdinger G, Brunauer R, Jamnig A, Laschober G, Kassem M. Controversial issue: is it safe to employ mesenchymal stem cells in cell-based therapies? Exp Gerontol 2008; 43(11): 1018–1023 Lazennec G, Jorgensen C. Concise review: adult multipotent stromal cells and cancer: risk or benefit? Stem Cells 2008; 26(6): 1387–1394 Närvä E, Autio R, Rahkonen N, Kong L, Harrison N, Kitsberg D, Borghese L, Itskovitz-Eldor J, Rasool O, Dvorak P, Hovatta O, Otonkoski T, Tuuri T, Cui W, Brüstle O, Baker D, Maltby E, Moore HD, Benvenisty N, Andrews PW, Yli-Harja O, Lahesmaa R. Highresolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nat Biotechnol 2010; 28(4): 371–377 Wong RS. Mesenchymal stem cells: angels or demons? J Biomed Biotechnol 2011; 2011: 459510 Rayment EA, Williams DJ. Concise review: mind the gap: challenges in characterizing and quantifying cell- and tissue-based therapies for clinical translation. Stem Cells 2010; 28(5): 996–1004 FDA. Guidance—Potency Tests for Cellular and Gene Therapy. 2011 Werner M, Mayleben T, Van Bokkelen G. Autologous cell therapies: the importance of regulatory oversight. Regen Med 2012; 7(6 Suppl): 100–103 Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM, Fries JW, Tiemann K, Bohlen H, Hescheler J, Welz A, Bloch W, Jacobsen SE, Fleischmann BK. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 2007; 110(4): 1362–1369 Moll G, Rasmusson-Duprez I, von Bahr L, Connolly-Andersen AM, Elgue G, Funke L, Hamad OA, Lönnies H, Magnusson PU, Sanchez J, Teramura Y, Nilsson-Ekdahl K, Ringdén O, Korsgren O, Nilsson B, Le Blanc K. Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cells 2012; 30(7): 1565–1574 FDA. US 21CFR211—Current Good Manufacturing Practice for Finished Pharmaceuticals. 2013 FDA. US 21CFR312—Investigational New Drug Application. 2013 FDA. US 21CFR610—General Biological Products Standards. 2013 FDA. US 21CFR1271—Human Cells, Tissues, and Cellular and Tissue-Based Products. 2013 US FDA. Draft Guidance—Preclinical Assessment of Investigational Cellular and Gene Therapy Products. 2012 US FDA. Draft Guidance—Design of Early-Phase Clinical Trials. 2013 George B. Regulations and guidelines governing stem cell based products: clinical considerations. Perspect Clin Res 2011; 2(3): 94–99 US Pharmacopeia. Cellular and Tissue-Based Products. General Chapter 1046. USP National Formulary. 2012 US Pharmacopeia. Ancillary Materials for Cell, Gene and Tissueengineered Products. General Chapter 1043. USP National Formulary. 2012 Hamburg MA. Increasing the Prestige of Regulatory Sciences. FDA Commissioner’s speech. 2011 Wagner BJ. Cell standardization: purity and potency. Regen Med 2012; 7(6 Suppl): 89–92 Buckler L. Why the stem cell sector must engage with social media. Regen Med 2012; 7(6 Suppl): 120–123 Krampera M, Galipeau J, Shi Y, Tarte K, Sensebe L; MSC Committee of the International Society for Cellular Therapy (ISCT). Immunological characterization of multipotent mesenchymal stromal cells—The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 2013; 15(9): 1054–1061